24/7 Wall St. Solithromycin is the company's potent fourth generation Macrolide antibiotic. The oral data in Phase 3 was out in January and was very positive. Its polymorph patent extends to 2032, which is significant. With other drugs also well along in clinical ...
Wall Street Journal (blog) Macrolide Pharmaceuticals, an anti-infectives drug maker, has launched with $22 million in Series A financing for the company. Investors in the Series A round include Gurnet Point Capital, Novartis Venture Fund, Roche Venture Fund and SR One.
Boston Business Journal (blog) Miller said the timing of the company's formation has to do with the development of a new process to create antibiotics – created by Macrolide co-founder and Harvard Professor Andrew Myers. Previously, the antibiotic could only be engineered within ...
Xconomy Newton, MA-based Macrolide has raised a $22 million Series A round from the venture arms of GlaxoSmithKline (SR One), Novartis (Novartis Venture Fund) and Roch...
Xconomy 3 Newton Executive Park Newton, MA 02462 USA; Company Description Macrolide Pharmaceuticals, LLC. is a new anti-infective company founded to advance groundbreaking technology developed by Professor Andrew Myers of Harvard University. Website
Medscape A gentleman who had undergone successful pulmonary-vein isolation in 2009 contacted me after he took a second dose of a macrolide antibiotic prescribed for bronchitis. His palpitations were so severe that he was convinced his atrial fibrillation had ...
Medscape Macrolide treatment of Mycoplasma pneumoniae may or may not benefit children with community-acquired lower respiratory tract infection (CA-LRTI), according to an article published in the June issue of Pediatrics. Eric Biondi, MD, from the Department of ...
Dairy Herd Management In a study reported this week in the journal Environmental Health Perspectives, researchers from the Department of Environmental Toxicology at Texas Tech University report detecting antibiotics and antibiotic resistance genes in particulate matter ... and more »
